Press release

SenzaGen secures order worth SEK 2.5 million from leading global tech company

SenzaGen has received an order from an existing customer in the technology sector. The assignment covers non-animal skin allergy testing using the GARD® platform, with a total value of approximately SEK 2.5 million. The order marks a further step into a relatively new and extensive customer segment, where the company’s experience and expertise in testing chemicals in solid materials have been key factors. The tests will be conducted at the company’s GLP-certified laboratory in Lund, with the majority scheduled for 2025.

The customer is a global leader with innovative consumer products. The tests aim to determine safe dose levels of chemicals in solid materials using GARD®skin Dose-Response, which is specifically optimized for this type of application.

"We are very pleased to have earned the continued trust of this important customer. It demonstrates the breadth of our expertise and the relevance of our unique technology beyond our traditional customer segments. This is our largest order so far this year, and we look forward to supporting the customer’s efforts to deliver safe and allergy-free products," says Peter Nählstedt, CEO and President of SenzaGen.

GARD®skin Dose-Response is a unique non-animal method that provides quantitative data and eliminates the need for animal testing. The method determines at which dose-level substances can be used in a product without causing skin allergies. Based on genomics and machine learning, it can be used as a stand-alone solution without the need for complementary test methods, giving companies across various industries a powerful decision-making tool when developing new products.

A strategic initiative is currently underway to have the method adopted as an OECD standard, which is expected to significantly increase the company’s sales in the coming years.

About us

SenzaGen is a corporate group on its way to becoming a leading player in non-animal testing, driving the shift from animal experiments to methods that more accurately reflect human biology. Leveraging cutting-edge technology, the company offers high-performance non-animal test methods and expert advisory services. These methods are more effective, precise, and cost-efficient than traditional animal-based approaches and contribute to a substantial reduction in the number of laboratory animals used worldwide. SenzaGen’s growth strategy focuses on strengthening its position in both established and new markets through direct sales, complementary partnerships, an expanded test portfolio, and recognized thought leadership. The company also maintains a long-term acquisition agenda to accelerate commercial potential. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden, along with subsidiaries in Italy and the USA. For more information, visit www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.